Begin with the document's exact scope
A COA can report one or more measured attributes for a named material or batch. Before interpreting a percentage, chromatogram, or spectrum, identify the document title, issuing organization, report number, analysis date, product name, labeled strength, and lot or batch identifier.
Do not treat the title “certificate of analysis” as proof that every possible attribute was tested. Read the tests actually listed, the method named for each result, the units or basis, and any stated acceptance criterion.
A result supports only the attribute measured under the stated procedure. It should not be expanded into unstated conclusions about content, sterility, endotoxin, residual solvents, biological activity, or suitability for a particular use.
Match the report to the physical lot
Compare the full product name, exact strength or variant, and lot or batch identifier across the vial label, order record, and analytical document. Copy identifiers exactly; a similar product name or neighboring lot is not a match.
- Product identityFull name, not a shortened family label.
- Labeled strengthThe exact variant shown on the vial.
- Lot or batchThe same identifier on both material and report.
- Report identityIssuing source, report number, and date.
If any linkage field is absent or inconsistent, keep the report separate and ask the issuer or supplier for clarification. Do not edit the report or infer a match.
What HPLC or liquid chromatography can show
Liquid chromatography separates a mixture into fractions with different compositions. A chromatogram shows detector response over the analytical run. When a report states a peak-area percentage, that number is tied to the sample preparation, column, detector, wavelength or detection mode, integration choices, and other conditions of that procedure.
| A stated result may support | It does not automatically establish |
|---|---|
| Separation and relative detector response under the stated method | The chemical identity of the main peak |
| A reported purity-related value on the method's stated basis | Total material content per vial or net peptide content |
| Comparison with the document's stated acceptance criterion | Sterility, endotoxin, residual-solvent, or biological-activity results |
A percentage without the method, basis, and sample linkage is incomplete context. A chromatographic retention time alone is also not necessarily a specific identity test; FDA's Q6A guidance expressly distinguishes retention time from more specific or combined identification approaches in its regulated scope.
What mass spectrometry or LC-MS can show
NIST describes mass spectrometry as a detection technique that uses differences in the mass-to-charge ratio of ions. A report may compare an observed ion pattern or derived mass with an expected value to support identity under the stated procedure.
| A stated result may support | It does not automatically establish |
|---|---|
| Mass-to-charge information consistent with an expected analyte | A complete sequence assignment unless the stated method supports it |
| Identity evidence when the procedure is appropriately specific | A quantitative purity percentage or total vial content |
| Detection combined with a chromatographic separation in LC-MS | Every impurity, contaminant, or unmeasured quality attribute |
Check whether the document provides the expected value, observed value, units, ion or charge-state information, and interpretation. If it only says “passed” without a result or acceptance basis, record that limitation rather than filling the gap yourself.
Why complementary methods matter
Identity and purity are different analytical questions. ICH Q2(R2) notes that a lack of specificity in one procedure may be addressed with one or more supporting procedures, and FDA's Q6A discussion gives combined approaches such as HPLC/MS as examples in its regulated drug context.
That does not mean two method names automatically make a report complete. Each procedure still needs a stated purpose, suitable performance, a linked sample, and an interpretable result. The practical review question is: Which attribute does each result measure, and what evidence remains outside the report?
Separate the result from the specification
A result is the reported observation. A specification or acceptance criterion is the limit, range, or other requirement against which that result is compared. Record both when both are present.
A result without a stated criterion may still be data, but the reviewer should not invent a pass/fail threshold. Likewise, a supplier's general website claim is not a substitute for the lot-linked result shown on the document.
Record what the document does not establish
A disciplined review includes limitations. Note missing lot linkage, missing method details, unstated units, absent acceptance criteria, unclear issuing source, or a test that does not answer the claimed question.
- No lot matchThe report cannot be confidently connected to the vial.
- No named methodThe basis for the result is unclear.
- No units or basisThe numerical result cannot be interpreted fully.
- No supporting outputRecord that the underlying chromatogram or spectrum was not supplied.
- No verification routeRecord whether the issuing source can be independently checked.
- Unmeasured attributesDo not convert silence into a passing result.
Free review tool
Use the 15-field documentation checklist
Download a clean CSV for lot linkage, method, result, criterion, evidence, and follow-up notes.
Primary references and methodology
Bio Peptides Labs reviewed public analytical-procedure references from ICH, FDA, and NIST and translated their vocabulary into a vendor-neutral document-reading workflow. The FDA and ICH sources concern regulated drug-development or quality contexts. Citing them here does not claim that a research-use-only material, supplier, or report is FDA approved, registered, or compliant with those frameworks.
- ICH Q2(R2): Validation of Analytical Procedures — intended purpose, specificity, validation, and supporting procedures.
- FDA: Analytical Procedures and Methods Validation for Drugs and Biologics — documentation of analytical methodologies in the guidance's stated scope.
- FDA / ICH Q6A: Specifications, Test Procedures, and Acceptance Criteria — distinctions among tests, procedures, criteria, identity, and purity.
- NIST: Liquid Chromatography — Introduction and Instrumentation — chromatography and separation principles.
- NIST: Mass Spectrometry Instrument Lab — mass-to-charge detection and LC-MS context.
Last source review: August 8, 2026. Educational content only; not laboratory, legal, regulatory, medical, or purchasing advice.